Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1997-11-18
2000-10-17
Yucel, Remy
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
435448, 435455, 435456, 4353201, C12N 1500
Patent
active
061329894
ABSTRACT:
The invention provides compositions of a non-adenoviral vector containing a polynucleotide sequence encoding adenoviral pTP operationally linked domain. The invention also provides compositions of an adenoviral pTP binding domain. The invention also provides methods for increasing the expression of a polynucleotide by expressing the polynucleotide in a non-adenoviral vector containing an adenoviral pTP binding domain in the presence of adenoviral pTP. The invention additionally provides methods to increase expression of a heterologous polynucleotide in an individual by obtaining cells from the individual, genetically altering the cells to express a non-adenoviral vector containing an adenoviral pTP binding domain and a gene encoding pTP and readministering the genetically altered cells to the individual.
REFERENCES:
patent: 4861719 (1989-08-01), Miller
patent: 4959317 (1990-09-01), Sauer
patent: 5124263 (1992-06-01), Temin et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5434066 (1995-07-01), Bebee et al.
Angeletti and Engler, "Tyrosine kinase-dependent release of an adenovirus preterminal protein complex from the nuclear matrix,"J. Virol. 70:3060-3067 (1996).
Anton and Graham, "Site-specific recombination mediated by an adenovirus vector expressing the cre recombinase protein: a molecular switch for control of gene expression" J. Virol 69:4600-4606 (1995).
Araki et al., "Site-specific recombinase, R, encoded by yeast plasmid pSR1" J. Mol. Biol. 225:25-37 (1992).
Fisher et al., "Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis" J. Virol. 70:520-532 (1996).
Fredman and Engler, "Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro," J. Virol. 67:3384-3395 (1993).
Gu et al., "Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting" Cell 73:1155-1164 (1993).
Hawley et al., "Versatile retroviral vectors for petential use in gene therapy," Gene Therapy 1:136-138 (1994).
Hodgson, C.P., "The vector void in gene therapy" Biotechnology 13:222-225 (1995).
Johnson et al., "Isolation of the gene encoding the hin recombinational enhancer binding protein" Proc. Natl. Acad. Sci. USA 85:3484-3488 (1988).
Kay et al., "Expression of human .alpha..sub.1 -antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes" Proc. Natl. Acad. Sci. USA 89:89-93 (1992).
Kay et al., "Hepatic gene therapy: persistant expression of human .alpha.1-antitrypsin in mice after direct gene delivery in vivo" Hum .Gene Therapy 3:641-647 (1992).
Kay et al., "In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs" Science 262:117-119 (1993).
Kay et al., "In vivo Hepatic gene therapy: Complete albeit transient correction of Factor IX deficiency in hemophilia B dogs" Proc. Natl. Acad. Sci. USA 91:2353-2357 (1994).
Kay et al., "Therapeutic serum concentrations of human alpha.sub.1 -antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes" Hepatology 21:815-819 (1995).
Kay et al., "Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration" Nature Genetics 11:191-197 (1995).
Kochanek et al., "A new adenoviral vector for gene therapy: Replacement of all viral coding sequences with 28 kb of foreign DNA" Am. J. Hu. Genetics [abstract] 57(4): A244 (1995).
Ledley et al., "Retroviral mediated transfer and expression of human alpha 1-antitrypsin in cultured cells" Gene 61:113-118 (1987).
Li et al., "Assessment of recombinant adenoviral vectors for hepatic gene therapy" Human Gene Therapy 4:403-409 (1993).
Marshall, E., "Gene therapy's growing pains" Science 269:1050-1055 (1995).
Mitani and Caskey, "Delivering therapeutic genes--matching approach and application" Trends Biotechnol. 11:162-166 (1993).
Mitani et al., "Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector" Proc. Natl. Acad. Sci. USA 92:3854-3858 (1995).
Naldini, et al., "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector" Science 272:263-267 (1996).
O'Gorman et al., "Recombinase-mediated gene activation and site-specific integration in mammalian cells" Science 251:1351-1355 (1991).
Onouchi et al., "Visualization of site-specific recombination catalyzed by a recombinase from Zygosaccharomyces rouxii in Arabidopsis thaliana " Mol. Gen. Genet. 247:653-660 (1995).
Rosenfeld et al., "Adenovirus-mediated transfer of a recombinant .alpha.1-antitrypsin gene to the lung epithelium in vivo" Science 252:431-434 (1991).
Scaria et al., "Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes" Gene Therapy 2:295-298 (1995).
van der Vliet, The molecular repertoire of adenoviruses vol. 2, pp. 1-31 Doerfler and Bohm, eds. Springer-Verlag, Berlin (1995).
Webster et al., "Activation of adenovirus-coded protease and processing of preterminal protein" J. Virol. 68:7292-7300 (1994).
Orkin et al. Report and recommendation of the panel to assess the NIH investment in research on gene therapy, Dec. 1995.
Freidman, T. Scientific American, pp. 96-101, Jun. 1997.
Verma et al. Nature. vol. 389, pp. 239-242, Sep. 1997.
van der Vliet, P.C. The molecular repertoire of adenoviruses. vol. 2, pp. 1-31. Doerfler adn Bohm. eds. Springer-Verlag, Berlin, 1995.
Schaack et al., Genes and Development. vol. 4, pp. 1197-1208, 1990.
Kay Mark A.
Lieber Andre
University of Washington
Yucel Remy
LandOfFree
Methods and compositions for enhanced stability of non-adenovira does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for enhanced stability of non-adenovira, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for enhanced stability of non-adenovira will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-467178